LabGenomics Co. Ltd Cash Flow Conversion Efficiency
LabGenomics Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, LabGenomics Co. Ltd (084650) has a cash flow conversion efficiency ratio of -0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-6.41 Billion ≈ $-4.35 Million USD) by net assets (₩188.67 Billion ≈ $127.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of LabGenomics Co. Ltd (2014–2024)
Cash flow conversion efficiency of LabGenomics Co. Ltd from 2014 to 2024. This chart illustrates how LabGenomics Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LabGenomics Co. Ltd stock quote for real-time trading data and today's change.
LabGenomics Co. Ltd Cash Flow Conversion Ratio Explained
LabGenomics Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
LabGenomics Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LabGenomics Co. Ltd ranked by their cash flow conversion efficiency. Also see how much is LabGenomics Co. Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Leyand International Tbk
JK:LAPD
|
0.140x |
|
Primega Group Holdings Limited
NASDAQ:ZDAI
|
-0.106x |
|
Four Leaf Acquisition Corporation Class A Common Stock
NASDAQ:FORL
|
-0.074x |
|
Admiralty Resources NL
AU:ADY
|
0.000x |
|
BSL Corp Bhd
KLSE:7221
|
-0.260x |
|
TAG Oil Ltd.
V:TAO
|
-0.021x |
|
i2S SA
PA:ALI2S
|
0.169x |
|
Tvardi Therapeutics, Inc.
NASDAQ:TVRD
|
-1.101x |
Annual Cash Flow Conversion Efficiency for LabGenomics Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of LabGenomics Co. Ltd from 2014 to 2024. Review 084650 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩216.31 Billion ≈ $146.59 Million |
₩-12.99 Billion ≈ $-8.81 Million |
-0.060x | -665.89% |
| 2023-12-31 | ₩228.14 Billion ≈ $154.61 Million |
₩2.42 Billion ≈ $1.64 Million |
0.011x | -96.82% |
| 2022-12-31 | ₩209.33 Billion ≈ $141.86 Million |
₩69.87 Billion ≈ $47.35 Million |
0.334x | -19.46% |
| 2021-12-31 | ₩157.72 Billion ≈ $106.88 Million |
₩65.36 Billion ≈ $44.29 Million |
0.414x | -27.12% |
| 2020-12-31 | ₩81.54 Billion ≈ $55.26 Million |
₩46.37 Billion ≈ $31.43 Million |
0.569x | +442.57% |
| 2019-12-31 | ₩30.42 Billion ≈ $20.61 Million |
₩3.19 Billion ≈ $2.16 Million |
0.105x | +418.90% |
| 2018-12-31 | ₩30.10 Billion ≈ $20.40 Million |
₩608.03 Million ≈ $412.05K |
0.020x | +142.71% |
| 2017-12-31 | ₩22.35 Billion ≈ $15.14 Million |
₩-1.06 Billion ≈ $-716.24K |
-0.047x | -146.58% |
| 2016-12-31 | ₩25.04 Billion ≈ $16.97 Million |
₩2.54 Billion ≈ $1.72 Million |
0.102x | -5.37% |
| 2015-12-31 | ₩22.15 Billion ≈ $15.01 Million |
₩2.38 Billion ≈ $1.61 Million |
0.107x | -27.59% |
| 2014-12-31 | ₩21.24 Billion ≈ $14.39 Million |
₩3.15 Billion ≈ $2.13 Million |
0.148x | -- |
About LabGenomics Co. Ltd
LabGenomics Co., Ltd. engages in the research and development of biotechnology products in South Korea. It is also involved in the sale of diagnostic devices. The company was founded in 2002 and is based in Seongnam-si, South Korea.